Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04223193 · ClinicalTrials.gov registry record · Phase 3
Flexible-Dose Trial in Early Parkinson's Disease (PD)
A Phase 3 study of Parkinson Disease, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
- 20
- Study locations
NCT04223193 is a Phase 3 study of Parkinson Disease that has completed, run by AbbVie. The registered enrollment target is 304 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04223193, a Phase 3 study of Parkinson Disease, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tavapadon
Study Locations (20)
Florida
- Boca Raton, Florida - Boca Raton
- Maitland, Florida - Maitland
- Ocala, Florida - Ocala
- Winter Park, Florida - Winter Park
Texas
- Cypress, Texas - Cypress
- Houston, Texas - Houston
- Lubbock, Texas - Lubbock
- Round Rock, Texas - Round Rock
New York
- Albany, New York - Albany
- Syracuse, New York - Syracuse
Ohio
- Cincinnati, Ohio - Cincinnati
- Cleveland, Ohio - Cleveland
Virginia
- Richmond, Virginia - Richmond
- Richmond, Virginia - Richmond
California
- Fresno, California - Fresno
Massachusetts
- Boston Neuro Research Center - North Dartmouth
Tennessee
- Memphis, Tennessee - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04223193
The ClinicalTrials.gov registry entry for NCT04223193 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04223193 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Texas, New York.
Frequently Asked Questions
What is clinical trial NCT04223193 about?
NCT04223193 is a clinical study titled "Flexible-Dose Trial in Early Parkinson's Disease (PD)". The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
What is the current status of trial NCT04223193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2020-01-06. Estimated completion is 2024-10-01.
What conditions does trial NCT04223193 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04223193?
The interventions under investigation include: Placebo (DRUG), Tavapadon (DRUG).
Who is sponsoring clinical trial NCT04223193?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04223193 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
RECRUITING · Phase 3
-
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
Embryonic Dopamine Cell Implants for Parkinson's Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.